Related Experiment Videos
Integrating New Approach Methodologies and Artificial Intelligence to Advance Central Nervous System Toxicity
Mamta Behl1, Fiona S Daly2, Helena T Hogberg2
1Neurocrine Biosciences Inc. San Diego, CA.
Summary
Predicting central nervous system (CNS) toxicities in drug development is challenging. This study explores advanced methods like AI and EEG to improve early detection of neurological risks, enhancing drug safety assessment.
Area of Science:
- Pharmacology
- Neuroscience
- Toxicology
Background:
- Central nervous system (CNS) toxicities are a significant hurdle in drug development, leading to high attrition rates.
- Current nonclinical methods for assessing neurotoxicity have limitations in predictive accuracy and translational relevance.
- Accurate prediction of neurological risk is crucial for safe and effective drug development.
Purpose of the Study:
- To examine the challenges in CNS safety assessment during drug development.
- To highlight emerging strategies for the early detection and prediction of neurological risks.
- To demonstrate practical approaches for interpreting CNS safety signals and integrating new methodologies.
Main Methods:
- Review of case studies focusing on sensory and seizure-related endpoints.
- Utilizing electroencephalography (EEG) for improved seizure liability detection.
- Application of advanced sensor technologies and artificial intelligence (AI) for continuous animal behavior monitoring.
- Implementation of an Integrated Approach to Testing and Assessment (IATA) combining mechanistic data, toxicology, and exposure modeling.
- Analysis of regulatory CNS case studies in drug development.
Main Results:
- Emerging strategies, including EEG and AI-powered monitoring, enhance the detection and characterization of CNS adverse effects.
- Integrated approaches (IATA) support regulatory decision-making and align with the 3Rs principles (replace, reduce, refine animal testing).
- Advanced methods enable quantitative assessment of neurological function and reduce reliance on subjective measurements.
Conclusions:
- Integrating refined in vivo methods with New Approach Methodologies (NAMs) and digital technologies improves the prediction of neurological risk.
- Enhanced CNS safety assessment strengthens the translation of nonclinical findings to human outcomes.
- These advancements are vital for overcoming challenges in CNS drug development and improving patient safety.
Related Concept Videos
01:28Preclinical Development: Overview
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
01:23Toxicity Testing in Animals
Toxicity tests in animals are grounded on two main assumptions: first, the effects observed in laboratory animals can be extrapolated to humans, especially when adjusted for body surface area; second, high-dose exposure in animals is essential to identify potential human hazards from lower doses. This is based on the quantal dose-response concept, which faces the challenge of extrapolating results from relatively few test animals to much larger human populations. For example, a 0.01% incidence...